Various stresses of the tumor microenvironment produced by insufficient nutrients, pH, and oxygen can contribute to the generation of altered metabolic and proliferative states that promote the survival of metastatic cells. Among many cellular stress-response pathways activated under such conditions are the hypoxia-inducible factor (HIF) pathway and the unfolded protein response (UPR), which is elicited as a response to endoplasmic reticulum (ER) stress. In this study, we report the identification of a novel cancer invasion and metastasis-related gene (hereafter referred to as CIM, also called ERLEC1), which influences both of these stress-response pathways to promote metastasis. CIM was identified by comparing the gene expression profile of a highly metastatic human lung cancer cell line with its weakly metastatic parental clone. We showed that CIM is critical for metastatic properties in this system. Proteomic approaches combined with bioinformatic analyses revealed that CIM has multifaceted roles in controlling the response to hypoxia and ER stress. Specifically, CIM sequestered OS-9 from the HIF-1a complex and PHD2, permitting HIF-1a accumulation by preventing its degradation. Ectopic expression of CIM in lung cancer cells increased their tolerance to hypoxia. CIM also modulated UPR through interaction with the key ER stress protein BiP, influencing cell proliferation under ER stress conditions. Our findings shed light on how tolerance to multiple cellular stresses at a metastatic site can be evoked by an integrated mechanism involving CIM, which can function to coordinate those responses in a manner that promotes metastatic cell survival. Cancer Res; 70(23); 9949-58. Ó2010 AACR.
Introduction
Lung cancer is the number 1 cause of cancer death in many economically developed countries including Japan, claiming an unacceptably large number of lives each year. Despite recent aggressive treatment approaches, and great strides in understanding its biology and the underlying molecular mechanisms (1), long-term survival rates remain unsatisfactory, with more than 50% of cases eventually suffering from widespread metastases or local recurrences after successful potentially curative resection (2) . Although cancer metastasis has been considered to arise from a minute fraction of primary cancer cells through multistep clonal evolutions, accumulating evidence points to the possibility that metastatic potential is acquired early in carcinogenesis, consequently conferring metastatic capabilities to the bulk of primary tumors (3, 4) . It is evidently an urgent need to elucidate how lung cancer cells give rise to distant metastasis to provide not only a better understanding of the underlying molecular mechanisms, but also reveal novel targets for greatly improved molecular diagnosis and therapeutic intervention.
Along this line, various investigators have shown that microarray analysis is a useful means to identify genes related to a metastatic phenotype (3, (5) (6) (7) . We have established a highly metastatic clone (NCI-H460-LNM35, hereafter referred to as LNM35) of a non-small cell lung cancer cell line, which helped us to identify the involvement of the COX-2, CLCP-1, and DLX-4 genes in lung cancer metastasis through microarray analyses (8) (9) (10) (11) (12) (13) . In addition, proteomics-based approaches, which are increasingly being used to gain insight into the molecular complexities of human cancers (14) (15) (16) (17) , have also been noted to be powerful in such studies (18) (19) (20) .
Emerging evidence suggests that various types of cellular stress from the insufficient microenvironment surrounding metastatic cells, such as restriction of nutrients, pH changes, and oxygenation are important contributing elements that induce an altered metabolic and proliferative status, which favors their survival in metastatic sites (21, 22) . Such microenvironment stresses activate a range of cellular stress-response pathways, including those mediated by the hypoxia inducible factor (HIF) family of transcription factors as well as unfolded protein response (UPR; refs. [21] [22] [23] [24] . HIF-1 is a transcription factor that transactivates target genes involved in survival, proliferation, angiogenesis, invasion, and metastasis (25) . HIF-1 is negatively regulated by von Hippel-Lindau (VHL) tumor suppressor-mediated ubiquitination, which also involves OS-9 and prolyl hydroxylases (26) (27) (28) (29) . UPR is a program of transcriptional and translational changes elicited as a response to endoplasmic reticulum (ER) stress and regulates the balance between survival and apoptosis, as well as between dormancy and aggressive growth of tumor cells (21, 22, 24) . However, little is known regarding the underlying mechanisms that perturb this balance, which contributes to tumor progression such as establishment of cancer metastasis.
In the present study, we identified a gene associated with various characteristics of a highly metastatic NCI-H460-LNM35 human lung cancer cell line and characterized it in detail in relation to cancer metastasis through a combined omics approach that utilized microarray and mass spectrometry with peptide tagging technology followed by bioinformatic analyses. Our findings suggest that CIM has multifaceted roles in cancer metastasis, by positively regulating HIF-1a expression as well as by modulating cytoprotective UPR.
Materials and Methods
Cell lines, lung cancer tissues, RNA extraction, and MTT assay NCI-H460 and 293T cell lines were used within 6 months of purchase from ATCC and maintained in Roswell Park Memorial Institute (RPMI) and DMEM with 10% fetal calf serum (FCS), respectively. ATCC provides molecular authentication in support of their collection. Establishment of NCI-H460-LNM35, a highly metastatic human lung cancer subline, and NCI-H460-N15, a low metastatic parental subline, has been reported previously (13) , and these cell lines were cultured in RPMI with 10% FCS. In our hypoxia culture, cells were placed in a multigas incubator (Sanyo) with 0.5% O 2 /5% CO 2 /balance N 2 and incubated at 37 C. Tumor and normal lung tissues were collected from patients diagnosed histologically as primary lung cancer, who underwent potentially curative resection at Aichi Cancer Center Hospital between January 1996 and January 1998 (3 SCLC, 6 adenocarcinoma, 6 squamous cell carcinoma, and 1 large cell carcinoma cases). Approval from the institutional review board and the patients' written informed consent were obtained. Staging was determined after pathologic evaluation of resected specimens according to the International System for Staging Lung Cancer. All tissues were quickly frozen in liquid nitrogen and stored at À80 C until analysis. RNA was isolated using RNAeasy (Qiagen) according to the manufacturer's instructions, and the quality was checked with 2100 Bioanalyzer (Agilent). 3-(4,5-Dimethylthiazol-2-yl) 2,5 diphenyltetrazolium bromide (MTT) assay was performed with TetraColor One according to manufacturer's instruction (Seikagaku), and triplicate independent experimental repeats were performed and the data analyzed all together.
Microarray and Northern blot analyses
A cDNA membrane microarray (GeneFilter Human Microarrays GF202; Invitrogen,), containing a total of 5392 spots corresponding to 5184 unique genes was used to analyze a set of total RNA extracted from LNM35 and N15 cells (5 mg each; ref. 8). We conducted 2 independent experiments, and the results from each were analyzed separately. Raw expression data for each gene were normalized within each of the hybridization results (for LNM35) using a global normalization method. The expression values of LNM35 were compared to those of N15, and array spots that met the following criteria were selected; differential expression at the level of more than 3-fold elevation or reduction in LNM35 cells in both of 2 independent experiments. Northern blot analysis using 10 mg each of the extracted total RNA samples were conducted using standard procedures.
Generation of CIM knocked down LNM35 cells by transfecting CIM-specific shRNA expression vector A CIM-specific shRNA expression vector and control vector were constructed by cloning annealed oligonucleotides of CIM-specific shRNA into pH1-RNAneo, in which gene expression is under the control of the RNA polymerase III H1-RNA gene promoter. LNM35 CIM-specific shRNA stable transfectants (clones #5-11, #6-4, #6-11, and #6-12) were generated by transfection of 2 mg of pH1-RNAneo-CIM-specific shRNA using FuGENE 6 reagent (Roche Applied Science). Cells were selected by the neomycin (1 mg/mL) for 2 weeks.
In vivo spontaneous metastasis assay Cells (1.0 Â 10 7 ) in 0.1 mL of serum-free RPMI 1640 medium were injected into the subcutaneous tissue of the right abdominal wall of six 6-week-old female SCID mice (CLEA Japan), which were maintained under specific-pathogen-free conditions. Forty days after inoculation, the mice were euthanized and their lungs, lymph nodes, and subcutaneous tumors were resected, weighed, and fixed with 4% formaldehyde. Lung-metastatic nodules were examined under a dissecting microscope. All the results presented were obtained by averaging these data. Animal care was in accord with institution guidelines.
Construction of the myc-tagged CIM expression vector and antibodies
Full-length CIM cDNA was generated by PCR using cDNA converted from normal lung RNA. The resultant PCR products were cloned into the pIRES-puro2-myc (Invitrogen) and sequenced thoroughly. To construct 2 expression vectors for an artificial truncation mutant that lacked the N-or Cterminal homologous region (HR) of OS-9, a myc-tagged CIM vector was constructed from pIRES-puro2-CIM-myc after digestion with BsrGI or EcoNI, respectively.
Antibodies, anti-myc, GRP75 and -LGALS3 (anti-myc for CIM detection, Santa Cruz Biotechnology), -HIF-1a and BiP (BD BioSciences), -OS-9 and -PHD2 (Novus), -KDEL, -GM130, caspase3, caspase8, PARP, IRE-1a, p38, and ERK (Cell Signaling) were used in this study.
Proteomic analysis
Cells were lysed with 100 mL of 0.5 mol/L TEAB containing 0.1% (w/v) SDS, as described previously (20) , and centrifuged at 18,000 Â g for 20 minutes at 4 C. One hundred micrograms of protein in the supernatants were labeled with iTRAQ (Applied Biosystems) according to the manufacturer's instructions. Peptide fractionation was performed using nano-HPLC (KYA Technologies) with trap, and strong cation exchange and reverse-phase (RP) analytical columns. The RP column eluate was analyzed using mass spectrometry (Q-STAR-XL; Applied Biosystems) and relative abundance of each protein was determined by the MS/MS scans of iTRAQ-labeled peptides. Proteins with more than 2-fold difference between VC and shCIM cells were analyzed further as candidate targets of CIM.
Gene ontology (GO; ref. 30) analysis was employed to highlight the functionally distinct biological features of a protein set associated with the acquisition of invasive and metastatic capabilities promoted by CIM in lung cancer cells, as described previously (8, 10) . Proteins affected by the change in CIM expression were linked to GO terms using Gene Spring (Agilent), and then were subjected to Fisher's exact test to identify which GO terms were over-or under-represented in a protein set of interest. Network analysis was conducted using the interrelation search mode of the KeyMolnet software (Medicinal Molecular Design) under the 2 "path limit" condition.
Immunoprecipitation
293T cells (3 Â 10 6 ) were transfected with 10 mg of myctagged CIM expression vectors. After 24 hours, the cells were lysed with PBS/0.1% Tween-20 and 500 mg of WCL was used for immunoprecipitation with an agarose conjugated antimyc antibody (Santa Cruz Biotechnology).
Analysis of XBP-1 splicing
First-strand cDNA was synthesized using SuperScript (Invitrogen). cDNAs were amplified with the 5 0 -AAGA-CAGCGCTTGGGGATGG-3 0 and 5 0 -TCCATGGGGAGATGTT-CTGG-3 0 primers, producing a 170-bp (unspliced) and a 144-bp fragment (spliced) that were separated on a 2% of agarose gel.
Microarray data
The present expression profile data are available at GEO as GSE16649.
Results

Search for genes associated with metastatic potential in human lung cancer cells
In the present study, we first compared the gene expression profile of a highly metastatic LNM35 clone with that of a low metastatic parental clone, N15, which was also derived from NCI-H460 (13) . Consequently, 6 genes, including 2 previously uncharacterized transcripts corresponding to an EST clone (T70922) and LOC441052, determined on the basis of a membrane microarray annotation, were found to be differentially expressed (Supplementary Table S1 ). Those 2 uncharacterized transcripts were selected for further analysis by quantitative PCR analysis using L2D2, a revertant clone of LNM35 with low metastatic characteristics (12) . We found that a transcript corresponding to T70922 was downregulated in L2D2 in association with the loss of metastatic ability. A subsequent in silico search using the EST clone revealed that the putative entire open reading frame covering T70922 was FLJ11051 (Genebank accession# AK001913), based on the corresponding full length cDNA clone.
Inhibition of metastatic phenotype of highly metastatic LNM35 cells in vivo
We initially generated knockdown clones of the identified candidate gene with potential activities related to cancer invasion and metastasis (hereafter, referred to as CIM, also called ERLEC1; ref. 31) using highly metastatic LNM35 cells by stably introducing shRNA (shCIM-LNM35 series), which produced clones with about a 5-fold reduction in CIM expression ( Supplementary Fig. S1 ) when compared with the control clones (VC-LNM35 series). Two control and 3 CIM knockdown clones of LNM35 were then injected into 6-week-old SCID (severe combined immune deficient) mice to investigate their effects on the metastatic capabilities of LNM35. All of the shCIM-LNM35 clones exhibited markedly diminished metastatic capabilities via lymphogenous routes (Fig. 1A, left graph) , whereas lung metastatic nodules of shCIM-LNM35 clones were significantly reduced in both number and size (Fig. 1A , middle graph and right photos). There were no distinctions in terms of in vivo growth at the primary sites (Fig. 1A, right graph) .
Analyses of subcellular localization of CIM
The CIM gene encodes a protein consisting of 483 amino acids with a mannose 6-phosphate receptor homology domain and HR to OS-9, which was previously isolated as a gene overexpressed in osteosarcomas (Fig. 1B, left; ref. 32 ). Although 2.5-kb-sized CIM transcripts were abundantly present in adult testis, skeletal muscle, pancreas, and prostate tissues ( Supplementary Fig. S2 ), 9 of 17 (53%) cell lines and 4 of 16 (25%) primary lung tumors obtained from patients exhibited increased CIM expression when compared with normal lung tissues ( Supplementary Fig. S3A and B) . We further examined the expression of CIM using our microarray dataset (10) and found that upregulation of CIM by more than 2-fold as compared with normal lung tissue was present in 23 of 149 (15.4%) non-small cell lung cancer cases ( Supplementary Fig. S3C ). The PSORT program (http:// psort.ims.u-tokyo.ac.jp/) predicted subcellular localization of CIM to be most likely in the ER. To confirm this prediction, we first constructed a myc-tagged CIM expression vector, as there are no CIM-specific antibodies presently available. As shown in Figure 1C , staining with the anti-myc antibody together with those for ER or Golgi detection clearly demonstrated that CIM localizes mainly in ER. In addition, the use of 2 artificial truncation mutants lacking each of the 2 HRs to OS-9 (Fig. 1B, right) revealed that the N-terminal HR was necessary for its subcellular localization in ER (Fig. 1D) .
Identification of a role of CIM in regulation of HIF-1a expression through modulation of OS-9 function.
ER is a key site of protein synthesis and serves a variety of general functions in protein modification. We therefore compared the protein expression profiles between shCIM-LNM35 and VC-LNM35 cells through a proteomic approach by mass spectrometric analysis to gain insight into the molecular function of CIM ( Fig. 2A) . Among 1,103 unique proteins identified, 27 proteins were upregulated (more than 2-fold) in shCIM-LNM35 cells, whereas 47 proteins were downregulated (less than 2-fold, Supplementary Table S2). We employed KeyMolnet software to explore possible networks affected by CIM and found 39 interrelations involving 42 proteins (Supplementary Fig. S4 ). We consequently noted that HIF-1 and HIF-1a were centered with several molecules downregulated in shCIM-LNM35 cells (Fig. 2B) . On the basis of these results, we speculated that changes in HIF-1a expression in shCIM-LNM35 cells might have been overlooked in our proteomic analysis, even though it is affected by CIM knockdown, possibly because the digested peptides of HIF-1a were coeluted together with those from other highly abundant proteins during liquid chromatography separation. In line with our expectation, comparison of HIF-1a expression between shCIM and VC-LNM35 cells clearly showed downregulation of HIF-1a specifically in shCIM-LNM35 cells under normoxic as well as prolonged hypoxic conditions (Fig. 2C) . We further investigated whether treatment with the MG132 proteasome inhibitor affected HIF-1a expression in shCIM-LNM35 cells, and found that acceleration of proteasome-mediated degradation might be involved in the downregulation of HIF-1a in cells knocked down for CIM (Fig. 2D) .
We next sought to verify the influence of CIM on HIF-1a regulation by transfecting CIM-specific siRNA molecules into LNM35 cells, which resulted in a less than 5-fold reduction in CIM expression (supplementary Fig. S5) , and found that downregulation of HIF-1a expression was observed in CIMknockdown cells, while expression of HIF-1ß was not affected (Fig. 3A) . Further verification by transiently transfecting CIM into N15 cells, which showed reduced expression of endogenous CIM ( Supplementary Fig. S3A ), was conducted and the results obtained revealed a positive effect of CIM on HIF-1a expression (Fig. 3B) . Next, we investigated the effects of CIM on proliferation under hypoxic condition. N15 cells were transiently transfected with either control or CIM-expression vectors, then cultured under normoxic or hypoxic conditions for the indicated time periods. Cell viability was analyzed by MTT analysis and we found that exogenous expression of CIM resulted in acquisition of tolerance-to-hypoxia (Fig. 3C) . To investigate whether tolerance-to-hypoxia in CIM-transfected N15 cells is due to upregulation of HIF-1a, we transfected HIF1a-specific siRNA into N15 cells expressing exogenous CIM. Knockdown of HIF-1a eliminated the acquisition of toleranceto-hypoxia in N15 cells induced by CIM (Fig. 3D) . To investigate the relationship between CIM and HIF-1a in vivo, Western blot analysis of HIF-1a expression was performed using both primary and metastatic tumors in the lungs of mouse xenografts of VC-and shCIM-LNM35 clones. We clearly detected reduced HIF-1a expression at the primary tumor sites of the xenografts of the shCIM-LNM35 clones, as compared with the VC-LNM35 clones ( Supplementary  Fig. S6A ). In contrast, HIF-1a was shown to be expressed in metastatic nodules in the lungs of the shCIM-LNM35 clones at a level noticeably closer to that observed in the A, schematic diagram of strategy used for proteomic identification of CIMregulated proteins. B, network analysis of proteins differentially expressed between LNM35 cells stably knocked down for CIM (shCIM) and corresponding empty vector control (VC) cells using KeyMolnet software based upon proteomic profiling. A selected portion surrounding HIF-1a is shown (see also Supplementary Fig. S4 ). Closed circles are proteins whose differential expression were observed through proteomic analyses. Fig. S6B ).
metastatic nodules of the VC-LNM35 clones (Supplementary
Our findings revealed that CIM played a role in positive regulation of HIF-1a expression. CIM is known to have homology with OS-9, which play a role in regulation of HIF-1a (27), accordingly we examined whether CIM functioned with OS-9. 293T cells were transiently transfected with wild-type or HR-truncated myc-tagged expression vectors of CIM, and subjected to immunoprecipitation followed by Western blot analysis with anti-myc and anti-OS-9 antibodies. It was clearly shown that wild-type CIM interacted with OS-9 and that both HRs were necessary for the interaction (Fig. 4A , top and bottom left). Since HR1 also appears to play a role in regulation of the subcellular localization of CIM (Fig. 1D) , it is possible that there are multiple functional domains within the HR1 region, including those for interactions with ER and OS-9. Accordingly, a future study delineating domains responsible for each interaction to clarify how CIM sequesters OS-9 in the ER would be interesting. We did not detect any interactions of CIM with either HIF-1a or PHD2 (Fig. 4A , top right, and bottom middle, and right), indicating that CIM binds only to OS-9 in the complex implicated in the degradation of HIF-1a protein. We further analyzed whether the interaction between OS-9 and CIM modifies the complex formation and found that the exogenous expression of CIM noticeably reduced the interaction between HIF-1a and OS-9, leading to upregulation of HIF-1a expression detected in whole cell lysates (Fig. 4B) . We also observed that transfection of OS-9-specific siRNA molecules into N15 cells, which showed reduced expression of endogenous CIM (Supplementary Fig. S3A ), resulted in upregulation of HIF-1a expression (Fig. 4C) . Furthermore, transfection of CIM-specific siRNA into LNM35 cells followed by transfection of either OS-9-specific or control siRNA revealed that downregulation of HIF-1a by siCIM is diminished by knockdown of OS-9 (Fig. 4D, left) .
Next, we analyzed the effects of CIM together with OS-9 on proliferation under hypoxic condition using LNM35 cells. shCIM-LNM35 cells were transiently transfected with either OS-9-specific or control siRNA, then cultured under normoxic or hypoxic conditions for the indicated time periods, and cell viability was analyzed by MTT analysis. We observed that knockdown of OS-9 partially alleviated hypoxia-induced growth retardation in LNM35 cells knocked down for CIM (Fig. 4D, right) . Accordingly, our observations suggested that CIM has an ability to regulate HIF-1a through sequestration of OS-9 from a complex with HIF-1a and PHD2, leading to inhibition of HIF-1a degradation and its consequential upregulation, and affect the tolerance-to-hypoxia, which may suppress tumor cells to proliferate in metastatic site.
Identification of another role of CIM for UPR
Proteomic analyses also revealed that elevated expressions of proteins implicated in protein folding, maturation, and transport, such as HSPB1, GRP75, and LGALS3 (33) (34) (35) , in shCIM-LNM35 cells, which we verified by Western blot analysis (Fig. 5A) . Furthermore, bioinformatic analysis revealed that GO term identifiers for the biological processes related to UPR (cellular response to ER stresses, P ¼ 0.0122), glycolysis (P ¼ 0.0129), and the protein metabolic process (P ¼ 0.0228) were observed more frequently than expected (P < 0.05) in the 74 proteins affected by CIM (Supplementary Table S3 ). Since some ER resident proteins are suggested to play roles in acquisition of aggressive phenotypes of human cancers by conferring adaptation of tumors to the microenvironment (21, 23, 36) , we speculated that CIM may also have an effect on the regulation of homeostasis of ER functions, modulating metastatic capability.
First, we analyzed the effects of CIM on proliferation under an ER-stressed condition induced by tunicamycin treatment and found a significant reduction in the growth of shCIM-LMN35 cells (Fig. 5B) , which was accompanied with increased levels of cleaved caspases-3 and -8, and PARP (Fig. 5C ), indicating that knockdown for CIM sensitized the LNM35 cells to the ER stress. Interestingly, we also observed an apparently impaired induction of BiP (Fig. 5D upper panel) , which is normally induced as a part of the manifestation of cytoprotective UPR signaling mediated by IRE1a (21), in tunicamycin-treated shCIM-LNM35 cells. Furthermore, activation of phosphorylation of IRE1a and ERK was also repressed, indicating that CIM is required for transduction of the adaptive signals in UPR (Fig. 5D upper panel) . We observed that IRE1a-mediated splicing of XBP-1 was clearly repressed in shCIM-LNM35 cells exposed to tunicamycin, reflecting impaired ER stress signaling through IRE1a (Fig. 5D lower panel) , whereas phosphorylation of p38, which occurs in response to ER stress, was found to be modestly affected ( Supplementary Fig. S7 ).
BiP is a key molecule in ER, which binds to IRE1a in nonstressed cells and maintains them in an inactive form, whereas accumulated unfolded proteins pull BiP away from IRE1a and triggers the downstream pathway of the UPR (37). Immunoprecipitation-Western blot analysis clearly demonstrated coimmunoprecipitation of BiP with myc-tagged CIM regardless of the presence of tunicamycin, whereas IRE1a was not present in the anti-myc immunoprecipitates (Fig. 6A) . Further investigation using immunoprecipitation with the anti-BiP antibody and subsequent Western blot analysis with the anti-IRE1a antibody revealed that dissociation of BiP from IRE1a in response to ER stress was markedly inhibited in LNM35 cells knocked down for CIM (Fig. 6B) . Although ER stresses imposed by an insufficient microenvironment have been suggested to play a suppressive role in the proliferation of cancer cells at metastatic sites (22, 23) , the present observations suggest that CIM confers tolerance to such ER stresses in cancer cells at metastatic sites and play a role in formation of metastasis, by allowing them to survive at metastatic sites.
Discussion
Cancer cells acquire abilities to cope with cellular stresses caused by an insufficient microenvironment in terms of nutrient supply, pH, and oxygenation, which eventually lead to their aggressive growth, metastasis, and poor response to therapy, and a number of cellular responses that have vital roles in survival under such stress conditions are thought to be crucially involved in this process. Among such stress responses the best understood is the one mediated by the hypoxia inducible transcription factor, HIF-1a, which activates the transcription of various target genes involved in angiogenesis, cell proliferation, invasion, and metastasis (25, 38) . In addition, the complex and multifaceted signal-transduction cascade of UPR, which serves to limit the accumula- Note that HIF-1a expression was increased in CIM-transfected cells in whole cell lysates. WCL, whole cell lysate. C, influence of CIM and OS-9 expression on HIF-1a regulation. Western blot analysis of N15 cells transfected with OS-9-specific siRNA showed increased HIF-1a expression. D, Western blot analysis of HIF-1a in LNM35 cells transiently transfected with CIM-specific siRNA (siCIM) followed by OS-9-specific siRNA (siOS9) or control siRNA (siCtrl) showed diminished effects of siCIM on HIF-1a expression in LNM35 cells followed by OS-9 knockdown (left panel). Results of MTT assay of LNM35 cells transfected with CIM-specific shRNA (shCIM #6-11) followed by either siOS9 or control siCtrl showed that knockdown of OS-9, known to be involved in HIF-1a degradation, partially alleviated hypoxia-induced growth retardation in LNM35 cells knocked down for CIM (right graph).
tion of misfolded proteins and also regulate programmed cell death, is another important mechanism to relieve stress imposed by the surrounding insufficient microenvironment (21, 22, 24) . The notion that hypoxia-induced HIF-1a-mediated response and UPR may have a functional link has recently attracted much attention (39, 40) , raising it as a key issue to further elucidate which pathway(s) and molecule(s) are involved in this new aspect of connection to stress responses. Our present findings demonstrate that CIM has multifaceted roles in 2 distinct stress responses, that is, regulation of HIF-1a expression and modulation of UPR, thus providing another layer to the link between the 2 stress responses (Supplementary Fig. S8 ).
HIF-1a is an oxygen-dependent transcriptional factor that plays important roles in enabling cells to survive in hypoxic conditions, as it activates the transcription of various target genes involved in angiogenesis, cell proliferation, invasion, and metastasis (25, 38) . A previous study showed that proteasomemediated degradation of HIF-1a is negatively regulated by OS-9, which carries regions homologous with CIM, through modulation of the formation of a complex between HIF-1a and PHDs leading to recruitment of VHL and eventual proteasomal degradation of HIF-1a (27) . The present study clearly demonstrated that CIM positively regulates HIF-1a expression by inhibiting its degradation through interaction with the negative regulator OS-9 and confers lung cancer cells tolerance-to-hypoxia allowing proliferation in a hypoxic condition. Given that HIF-1a is thought to play critical roles in tumor progression (25, 38) , it is conceivable that CIM contributes to promotion of aggressive growth of tumor cells in metastatic sites, in which cells must survive with a low supply of oxygen provided from the surrounding microenvironment, by positively regulating HIF-1a.
The UPR process has been suggested to poise cancer cells between apoptotic responses, dormancy, and aggressive growth, however, it remains to be clarified how it is controlled and which molecules are involved (21, 22, 24) . Results of our proteomic GO term analysis suggest a possible link between CIM and another important cellular stress response, UPR. We further demonstrated that CIM is involved in ER stress-induced dissociation of BiP, a major ER chaperon with a key role in UPR, from IRE1a and consequential activation BiP and ERK, which protects cells from apoptotic cell death under ER-stressed conditions (36, 41) . These findings suggest that CIM may contribute to tumor progression by protecting lung cancer cells from apoptosis under ER-stressed conditions, which are Arrowheads indicate cleaved forms. D, Western blot analysis of BiP, total and phosphorylated-IRE1a (t-and p-IRE1a, respectively), and total and phosphorylated-ERK (t-and p-ERK, respectively) expressions in shCIM and VC clones cultured in the presence or absence of tunicamycin (upper panel). XBP-1 splicing analysis was performed with RT-PCR using primers, which were used to amplify a fragment of XBP-1 harboring the region of IRE1a-mediated splicing. XBP-1 splicing in cells exposed to tunicamycin was clearly repressed in shCIM-LNM35 cells, which indicated impaired ER stress signaling through IRE1a (bottom).
conceivably encountered by cancer cells in the process of metastasis (36) . It is also important to note that while ERLEC1, synonymous with CIM and originally identified as a Krm2-binding protein, has been shown to function in N-glycan recognition in ER with a possible role in glycoprotein traffic and organogenesis in Xenopus (31), XTP3B/c2orf30 (also synonymous with CIM) was later reported to form a quality control complex in ER, thus eliminating misfolded proteins through ubiquitination in the ER (42, 43) . Our findings indicate that CIM/ERLEC1/XTP3-B plays another distinct function at ER by sequestering BiP and consequentially modulating IRE1a-mediated ER stress signals, suggesting a buffering role of CIM in the regulation of UPR initiated by ER luminal stress, after which it is transmitted to the cytosol and nucleus.
The present results provide evidence of another layer to the link between hypoxia-induced HIF-1a-mediated response and UPR via the multifaceted roles of CIM, which were identified in our search for a gene involved in metastatic processes of lung cancer. Emerging evidence indicates that agents that inhibit HIF-1a and/or key UPR signaling molecules could define a new type of cancer therapy that prevents adaptation of tumors to a hostile environment (25, 44) . Given that it has multifaceted roles in these signaling pathways, further clarification of the functional roles of CIM including that in normal cells under physiological conditions is apparently warranted. Those results should provide insight into how cancer cells acquire metastatic capabilities for survival and colonization at metastatic sites under stressful conditions, which may ultimately aid in development of a novel therapeutic strategy aimed at reducing the large number of deaths caused by this devastating disease.
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